Why the study?
Does the measurement of NT-proBNP and hs-cTnT improve the prediction of cardiovascular events and death in patients with type 2 diabetes?
Does the measurement of NT-proBNP and hs-cTnT improve the prediction of cardiovascular events and death in patients with type 2 diabetes?
NT-proBNP and hs-cTnT significantly improve risk classification for cardiovascular events and death in patients with type 2 diabetes beyond established risk predictors.
No takes yet. Share an insight, caveat, or question.
May enhance CV risk stratification in type 2 diabetes beyond traditional factors; leaves open whether measurement improves outcomes in prospective trials.
Hillis et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: